氨酸激酶抑制剂的心血管毒性风险评估:使用VigiBase数据库的药监测研究
Yusuke Igawa1,2, Hirofumi Hamano1,2, Satoru Esumi3
1Department of Clinical Pharmacology and Pharmacy, Okayama University, Okayama, Japan.
Frontiers in pharmacology
|December 17, 2024
概括
氨酸激酶抑制剂 (TKIs) 可能导致心脏毒性. 这项研究发现,在不同的TKI中,心脏风险各不相同,这突显了个性化患者监测和管理策略的必要性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 氨酸激酶抑制剂 (TKIs) 是重要的向癌症疗法.
- 心血管TKI的副作用可能会对患者的预后产生负面影响.
- 评估TKI相关的心脏毒性对于改善癌症幸存者的结果至关重要.
研究的目的:
- 评估与各种氨酸激酶抑制剂 (TKI) 相关的心脏毒性风险.
- 确定与心脏毒性风险增加相关的特定TKI和患者人口统计数据.
主要方法:
- 从世界卫生组织全球数据库,VigiBase (至2022年12月) 中对疑似不良药物反应的横截面分析.
- 用不成比例性分析 (报告的几率比率) 来识别FDA批准的TKI的心血管功能障碍信号.
- 根据患者年龄和性别进行分层分析,统计学意义设置为P < 0.05.
主要成果:
- 在17个TKI中检测到显著的心血管信号,包括erlotinib,gefitinib和imatinib.
- 分层分析显示,不良心血管事件的性别和年龄相关差异.
- 像lapatinib (男性) 和gefitinib (年轻患者) 等特定的TKI显示出了显著的信号.
结论:
- 根据向性激酶 (例如,VEGFR,EGFR) 分类的不同TKI具有不同的心脏毒性风险概况.
- 个性化风险评估和量身定制的管理对于接受TKIs的患者至关重要.
- 了解TKI相关心脏毒性有助于制定更安全,个性化的癌症治疗计划.
相关概念视频
01:19Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
100
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
100
01:07Teratogenicity
2.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K
01:13Therapeutic Index
4.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K
01:30Drug Binding to Blood Components
109
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
109